Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/be-power-tech">Be Power Tech</a> Pioneering energy-efficient climate control through the development of natural gas-powered air conditioners that also generate electricity. Private 2015 View Profile
<a href="/venture-capital/all-companies/evelo-biosciences">Evelo Biosciences</a> Transforming cancer therapy through a deep understanding of the cancer microbiome. Private 2015 View Profile
<a href="/venture-capital/all-companies/codiak-biosciences">Codiak BioSciences</a> Leading developer of exosome-based diagnostics and therapeutics. Private 2015 View Profile
<a href="/venture-capital/all-companies/kaleido-biosciences">Kaleido BioSciences</a> Private 2015 View Profile
<a href="/venture-capital/all-companies/rubius-therapeutics">Rubius Therapeutics</a> Pioneering a new therapeutic modality using genetically modified red blood cells to create Red-Cell Therapeutics™ with the potential to treat diverse areas of high unmet medical need. Private 2014 View Profile
<a href="/venture-capital/all-companies/cibo-technologies">CiBO Technologies</a> CiBO Technologies is improving the efficiency of farming while reducing its environmental impact, addressing the world's food security concerns, and making the planet a better place to live. Private 2015 View Profile
<a href="/venture-capital/all-companies/cadena-bio">Cadena Bio</a> Cadena Bio is developing revolutionary ingredients that feed and nourish the human microbiome. Private 2016 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Developing innovative diagnostic products to improve patient health. Public 2006 View Profile
<a href="/venture-capital/all-companies/seres-therapeutics">Seres Therapeutics</a> Developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. Public 2012 View Profile
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Leading genome editing company translating its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases. Public 2013 View Profile